Study finds GLP-1 drugs can help curb SUDs
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use disorders, including for alcohol, cannabis, nicotine, cocaine and opioids. The study examined records of more than 600,000 patients from the Department of Veterans Affairs who had Type 2 diabetes and took a GLP-1 or a sodium-glucose cotransporter-2 inhibitor, or SGLT2, for treatment. Additionally, the study found that people with pre-existing SUDs who took GLP-1 drugs had reduced risks of SUD-related emergency room visits, hospital admissions, overdose, suicide and death.
Related News Articles
Headline
In this conversation, three leaders from CommonSpirit Health explore how the organization is confronting stigma about substance use head-on through education,…
Headline
The Health Resources and Services Administration will award grants to rural hospitals and other providers from two areas of its Rural Communities Opioid…
Perspective
May is Mental Health Awareness Month, a time to elevate a conversation that hospitals and health systems live every day. Behavioral health is inseparable from…
Headline
The Food and Drug Administration today announced it is accelerating regulatory action on a new class of psychedelic-based therapies, following an April 18…
Headline
Americans across 43 states enrolled in health plans from the nation’s four largest commercial health insurers face potential disparities in finding in-network…
Headline
The cigarette smoking rate among U.S. adults dropped to 9.9% in 2024, the lowest level ever recorded, according to a report by the New England Journal of…